Summit: Phase III Trial Of Ivonescimab Plus Chemotherapy Shows Positive Results In EGFR-Mutant NSCLC

(RTTNews) – Summit Therapeutics Inc. (SMMT) announced Friday positive topline results from the Phase III clinical trial, HARMONi, evaluating ivonescimab plus chemotherapy in patients with EGFR-Mutant non-small cell lung cancer or NSCLC.

admin